Evolving Use of ICIs and Targeted Tx in NSCLC and SCLC

In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.

In this video, Apar Ganti, MD, highlights recent advances and studies presented at ASCO 2018 on management of NSCLC and SCLC with ICIs and targeted agents.

Related Content:

American Society of Clinical Oncology Annual Meeting (ASCO)Lung CancerImmunotherapy
Optimizing Sequencing of Novel EGFR-Targeted Agents in NSCLC
Novel Agents Targeting EGFR Mutations in Non–Small Cell Lung Cancer
Understanding the Impact of EGFR Mutations on NSCLC Management